Merck & Co.Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Merck & Co.Diversified pharma anchored by Keytruda, vaccines, and animal health. Entered the obesity pill race in December 2024 by licensing Hansoh's oral small-molecule GLP-1 agonist HS-10535 for $112M upfront and up to $1.9B in milestones; that asset is still preclinical. Its clinical-stage metabolic asset is efinopegdutide, a weekly GLP-1/glucagon co-agonist in Phase 2b for MASH.
Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.
SEC filings for this company are not available at the moment.